CardioMEMS, an Atlanta-based medical technology company, has developed a wireless sensing and communication device designed to help patients and physicians manage cardiovascular diseases, such as heart failure, aneurysms, and hypertension. Originally developed by Georgia Tech and MIT, the microelectromechanical system (MEMS) was licensed in 2001.
The CardioMEMS miniature wireless sensor is implanted in the body using a minimally invasive, catheter-based procedure. Once in place, the device transmits real-time data on cardiac output, blood pressure, and heart rate. This information can be measured and displayed using an electronic monitor system which can be accessed by the patient’s physician.
In 2007, the U.S. Food and Drug Administration approved CardioMEMS’ first product, the EndoSure™ Wireless Pressure Measurement System, an implantable device for measuring intrasac pressure during thoracic aortic aneurysm repair. The Endosure sensor, based on intellectual property from Georgia Tech, measures blood pressure, heart rate, and cardiac output for patients who have an abdominal aortic aneurysm. Ruptures from a weakened lower aorta rank as the 13th leading cause of death in the United States.
CardioMEMS provides frequent, on-demand, real-time monitoring of vital information to enable proactive patient management, reduced hospitalizations, improved quality of life for patients, and more efficient and cost-effective health care. The company announced in 2010 that it received $37.9 million in venture financing, a deal that propelled the company to the top of the PricewaterhouseCoopers Georgia Top 25 Venture Capital Deals listing.